Biotechnology company Intrexon Corporation to transfer its stock listing to Nasdaq

Intrexon will join Nasdaq’s community of 98% of U.S. listed biotech companies.

Biotechnology company Intrexon Corporation to transfer its stock listing to Nasdaq

By Jordan Saxe, Head of Healthcare Listings at Nasdaq

I am very pleased to share that Intrexon Corporation (Ticker: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, has announced it is transferring its stock exchange listing from the New York Stock Exchange to Nasdaq. Intrexon will begin trading on the Nasdaq Global Select Market on September 25, 2018.

Nasdaq is the leading exchange for the biotechnology sector with 98% of all U.S. listed biotechnology companies listed on our market. Since 2013, 220 biotechnology companies have listed on Nasdaq, raising $17.2 billion in new proceeds.

When considering our long-term partnership, companies choose to move to Nasdaq for our cost effective fee structure, superior market model, industry leading intelligence services, visibility platforms, and exchange-specific index inclusion opportunities. In particular, the Nasdaq Biotechnology Index represents a strong listing advantage as the index has grown over 700% in the past decade, now with $9.8 billion in assets.

Intrexon Tower Shot

We welcome Intrexon to our family of innovative biotechnology companies; Intrexon will begin trading on the Nasdaq Global Select Market on September 25, 2018.

Commenting on the announcement:

"Following a careful review, we have concluded that our shareholders will be served better by our listing on Nasdaq, with its superior technology, trading liquidity, visibility and opportunities for investor outreach," said Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon. "We look forward to our partnership with Nasdaq.”

"Intrexon has been driving innovation in the biotechnology industry with its development and engineering in synthetic biology," said Nelson Griggs, President of Nasdaq Stock Exchange. "As home to the leading biotechnology companies, we are excited to be their exchange partner as the company strives to help address some of the world's most pressing challenges.

Intrexon follows recently announced transfer United Continental Airlines and the over $1.3 trillion in market cap that has transferred to our market in recent years, including PepsiCo, Principal Financial Group, Xcel Energy, Walgreens Boots Alliance, Marriott International and Kraft Heinz.

To learn more about the advantages of a Nasdaq listing, please do not hesitate to contact me at Jordan.Saxe@nasdaq.com.

Jordan Saxe

Jordan B. Saxe is Senior Managing Director, Listing Services at Nasdaq. He is responsible for leading business development efforts in the healthcare sector, and brings over thirteen years of experience within the exchange field. He has advised over 200 IPOs and has worked closely with venture capital, private equity and investment firms to educate them on the liquidity options Nasdaq can provide. He holds a B.S. in Business Administration from the University of Vermont.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security, sector, or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding sector performance and specific companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

Recent posts{{catTitle ? " in " + catTitle : ""}}
{{post.Date | date:'MMM d'}}
Scroll up